Argos Therapeutics (NASDAQ: ARGS) has appointed Richard Katz the Durham, NC-based immune-oncology company’s new CFO. Katz was most recently CFO of Viamet Pharmaceuticals, also based in Durham. Previous roles include serving as CFO of Durham-based Icagen, and working as an executive in Goldman, Sachs & Company’s (NYSE: GS) healthcare group.
Katz holds a medical degree from Stanford and an MBA from Harvard. Argos is currently in late-stage clinical trials on its experimental kidney cancer treatment.